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Abstract. C3-Cloud is a project aiming to provide an ICT infrastructure, which will 
allow patient centric and integrated care, based on best practice guideline, for 
patients with multi-morbidity. The collaborative cure and care plan lies at the heart 
of the system, allowing healthcare professionals to manage the patients’ conditions. 
Clinical Decision Support, enhances this capability by offering recommendation 
based on guidelines, but also checking the patient’s record for known adverse 
interactions when the medication changes. The drug interaction advisory service 
provides recommendations in the three languages used in the project’s pilot sites, 
for over 1000 substances, based on the UK’s NICE BNF body of knowledge. The 
service can be integrated with any system using its RESTful API and by rendering 
results in JSON. 
Keywords. Drug interactions, pharmacovigilance, multi-morbidity, clinical 
decision support 
1. Introduction 
C3-Cloud is an e-health ICT system, offering integrated, patient-centered care, 
considering all aspects of multi-morbidity, creating a collaborative environment for all 
involved stakeholders [1]. The navel of the system consists of the patient care plan, a 
digital shared picture of the patients’ needs and care regime. The care plan allows all 
professionals to review and understand the implications of one condition in the presence 
of others; this by its nature is complex, containing a considerable amount of diverse 
information. Navigating, understanding, and interpreting all the information can be 
confounding. The C3-Cloud Clinical Decision Support service (CDS) offers an 
automated means of interpreting the available data. CDS connects to the care plan 
repository, and continuously searches records for relevant data. One of the CDS services 
focuses on potential drug-drug interactions. The current implementation of C3-Cloud 
cares for multi-morbidity patients with up to four conditions, including diabetes, renal 
failure, chronic heart failure, and depression. Medication regimes for this combination 
of conditions may include drugs that when combined, may result in adverse reactions [2]. 
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Drug Interaction Advisory Service (DIAS) is part of the C3-Cloud CDSS, offering 
advisories of potential interactions.  
2. Drug Interactions Service Architecture and Integration with C3-Cloud 
C3-Cloud has adopted a modular architecture, which can be deployed locally on an 
organization’s intranet, as well as a distributed system; depending on the scale and 
integrated care model [3] requirements of the service that needs to be offered to patients.  
 
 
Figure 1. a) C3DP (care plan) medication prescription view (top) b) test extract from the interactions 
notification pop-up dialogue (bottom); it gives interactions between diuretics (ATC: C03) and existing 
medication in the patient’s record. 
The Patient Empowerment Platform (PEP) provides a dedicated interface 
module to the patient, adapted to their needs. The Coordinated Cure and Care Delivery 
Platform (C3DP), shown in figure 1a, offers the interface to healthcare professionals, 
who will create, monitor, negotiate and customize a care plan with the patient. When 
loading a care plan from the repository, the C3DP will interact with the Clinical Decision 
Support (CDS) service, and will receive a number of automated recommendation. All 
communication amongst C3-Cloud components, as well as storage of information is 
achieved by accessing FHIR resources. 
Healthcare professionals can amend a patient’s medication via the C3DP. When 
a new medication request is entered the C3DP will issue a request to DIAS with the ATC 
codes of the patient’s medication. DIAS will then return a list of all the identified 
interactions amongst the substances that correspond to the ATC codes. The service can 
check all codes in a record, as well as only potential interactions of a newly prescribed 
medication. The latter is the default notification method, by a pop-up dialogue, to avoid 
fatigue alert. DIAS is accessed via a RESTful API using a GET request, and returns the 
results in JSON. Figure 2 shows an example of a request checking 3 ATC codes (Fig.2a), 
and an extract in JSON (Fig.2b) from the returned result. The JSON results are then 
presented in a friendlier format, in a pop-up dialogue (Fig.1b), once the user clicks the 
save prescription button, and only if interactions are found. The service returns an 
advisory and does not make any decisions. Furthermore, users are advised that lack of 
interactions, may not necessarily mean that there are not any, as this is limited to the 
knowledge body of the specific database.  
 
Figure 2. a) A typical DIAS GET request (top) b) extract from interactions returned in JSON (bottom). 
3. Design of the Drug Interactions Advisory Service  
DIAS implements the interactions between drugs, as specified by the National Institute 
of Care Excellence's implementation of the British National Formulary (BNF) [4]. BNF 
is a pharmaceutical reference book, used by the UK NHS. The information provided by 
the service, includes potential adverse interaction between substances, the effects of the 
interaction, the severity of the interaction, as well as the evidence basis of interaction.  
 
 
Figure 3. The DIAS Database Model. 
For example, Acarbose is a drug active ingredient Alpha-glucosidase inhibitor, 
commonly used by patients with type 2 diabetes, which reduces the effects of 
carbohydrates on blood sugar. Acarbose is listed as having a pharmacokinetic interaction 
with the active ingredient Digoxin used in patients with congestive heart failure to 
improve quality of life and prevent hospitalisation. The interaction is listed as moderate 
in criticality, having an effect as decreasing the concentration of Digoxin. The 
information is encoded as a database using as the international nonproprietary name 
(INN) of each substance. Substances have been matched to the ATC codes automatically 
using the NCBO BioPortal’s [5] mappings, whereas the ATC codes in the patient’s care 
 
GET    https://DIAS_Service_Host/ATC?code=J01CA04,B01AA03,G03XA01 
{ 
"DIAS_id": 101762, 
"chemical": "Warfarin", 
"chemical_ATC_code": "B01AA03 ", 
"interactant": "Amoxicillin", 
"interactant_ATC_code": "J01CA04 ", 
"interaction_criticality": "Severe", 
"interaction_effect": "Amoxicillin potentially alters the anticoagulant effect of warfarin. 
              Manufacturer advises monitor INR and adjust dose.", 
"interaction_effect_ES_auto": "La amoxicilina altera potencialmente el efecto anticoagulante de la 
              warfarina. El fabricante aconseja monitorizar el INR y ajustar la dosis.", 
"interaction_effect_SV_auto": "Amoxicillin förändrar potentiellt warfarins antikoagulerande  
              effekt. Tillverkaren rekommenderar att INR kontrolleras och dosen justeras.", 
"interaction_evidence_basis": "Anecdotal" 
}, 
plan have been coded by C3-Cloud clinicians. The mapping was tested with random 
sampling covering 50 substances. The current database contains over 50,000 interacting 
pairs of substances for over 1,000 substances. Figure 3 shows the logical view of the 
DIAS database. Medication and ATCCode are data from the FHIR repository, accessed 
through the C3DP, whereas Substance and Interaction are the DIAS entries. Substances 
are associated through an Interaction, which serves as an association class. Severity of 
an Interaction can have the values Severe, Moderate, Mild and Unknown, and 
EvidenceBasis can be a Study, Anecdotal or Theoretical. The effect of an interaction has 
been translated, in addition to English, to Spanish and Swedish so that can be used in the 
pilot sites where the system will be deployed. Translation was done using an automated 
translation service, and tested with manual random sampling. C3DP gives the option to 
users to access the original language as well as to flag a translation issue.  
In the ATC classification, substances are classified in a 5-level hierarchy, which 
from the higher to the lower level contains: anatomical main group, therapeutic 
subgroup, pharmacological subgroup, chemical subgroup and chemical substance [3]. 
The hierarchy of ATC codes allows for further flexibility, offering identification of 
potential interactions between substance and classes of medication. For example, the 
service can check for interactions between plain ACE inhibitors (C09AA) which is a 
chemical subgroup, with blood glucose lowering drugs, excluding insulins (A10B), 
which is defined at the pharmacological subgroup. Although this trades coverage for 
accuracy (54 interactions), this was considered a more realistic implementation as in 
many cases, patient records will contain information that matches a higher ATC level. It 
was decided that the advisory should be offered to healthcare professionals who could 
investigate further.  
4. Summary 
The Drug Interaction Advisory Service is a component of the C3-Cloud integrated 
care for multi-morbidity, IT infrastructure. It provides the system with over 50,000 
interactions between chemical substances, in three languages. DIAS has a RESTful API 
and returns results in JSON, which are shown during medication changes in a patient’s 
care plan. Future work will extend DIAS to include advisory on probability of side-
effects. 
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